Clinical Trials Logo

Immune Response clinical trials

View clinical trials related to Immune Response.

Filter by:

NCT ID: NCT05515263 Recruiting - Immune Response Clinical Trials

Snack Foods and Their Impact on the Immune Response Following Influenza Vaccination

NutrImmune
Start date: September 9, 2022
Phase: N/A
Study type: Interventional

The purpose of this study is to evaluate the impact of replacing usual snacks with alternative snack foods on the immune response to influenza vaccination in a population of healthy, middle-aged adults.

NCT ID: NCT05313451 Completed - Immune Response Clinical Trials

Evaluation of the Effect of a Soluble Fiber Consumption on Immunity Response

NUTIVAC
Start date: February 7, 2022
Phase: N/A
Study type: Interventional

At European level, the European Food Safety Agency has recognized two claims relating to the effects of prebiotics on the gastrointestinal sphere and on the immune system. In subjects aged 45-63, it was shown that a pre- and post-vaccination inulin consumption of 8g/day significantly increased the titer of antibodies directed against the H3N2 viral strain. The increase in bifidobacteria in the faeces confirmed that this effect was related to prebiotic capacities. The effect of prebiotics and probiotics on the immune response to influenza virus vaccination has been studied in two systematic reviews and meta-analyses. The authors show that the consumption of prebiotic fibers such as FOS, GOS, inulin, was also effective on the H3N2 strain, as on the H1N1 and B strains (antibody titers of 19.5%, 20.0% and 13.6% higher, respectively, compared to placebo). The soluble fiber under study is a resistant dextrin meeting the definition of a prebiotic fibre. The prebiotic properties have been demonstrated in humans in several studies for doses ranging from 10 to 20 g/day. Similarly, studies show that the effects on immune functions are favorably impacted by a consumption of 10 g/day for 8 weeks . These results confirm those of a preclinical study conducted in mini-pigs. The main objective of these study is to demonstrate that these prebiotic properties could help stimulate the post-vaccination immune response, and more specifically the production of antibodies directed against seasonal influenza viruses (following vaccination), and modulate the pro- and anti-inflammatory responses.

NCT ID: NCT05313139 Recruiting - Immune Response Clinical Trials

Surveillance of Vaccine-induced Immunity Against Ebola in Previously Vaccinated Health Care Workers

EBOSURV
Start date: December 13, 2021
Phase:
Study type: Observational

During the previous Ebola virus disease (EVD) outbreaks, the institute National de Recherche Biomédicale (INRB) and other institutional's staff in Democratic Republic of the Congo (DRC) got vaccinated with the rVSV-ZEBOV vaccine. However, the longevity of Ebola virus (EBOV)-specific immune responses after vaccination has not been studied extensively (only 1-2 years) nor comprehensively (only humoral), despite the wide use of this vaccine. With the re-emergence of Ebola in North-Kivu from a previously vaccinated individual, and the new planned vaccination campaign (considering homologous booster doses for previously vaccinated HCW) in light of the new outbreak in Beni, assessing the persistence and quality of vaccine-induced anti-EBOV immune responses is pertinent and timely.

NCT ID: NCT05208060 Not yet recruiting - Immune Response Clinical Trials

Study to Evaluate the Ability of Sublingual MV130 to Induce the Expression of Trained Immunity in Peripheral Blood Cells

Start date: June 1, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

A mechanistic clinical trial with the aim to evaluate whether MV130 can induce the expression of a particular immune response (trained immunity) in peripheral blood cells. Therefore, the investigators are not evaluating efficacy in any disease or medical condition but rather assessing the immunological effect in immunogenicity of MV130 in healthy volunteers.

NCT ID: NCT05102669 Completed - COVID19 Clinical Trials

Spike-specific Cellular Immune Response After COVID-19 Vaccination

RIS-COV
Start date: March 12, 2021
Phase:
Study type: Observational

Aim of this study is to evaluate whether COVID-19 vaccination induces a persistent cellular immune response. To this aim, blood samples are taken from vaccinated individuals and not immunized subjects as a control group. Cells isolated from blood samples are tested in vitro to assess the percentage of spike-specific T and B lymphocytes 1 and 7 months after a second dose of Comirnaty vaccine.

NCT ID: NCT05031663 Completed - Inflammation Clinical Trials

Effect of Almonds on Immune Strength and Response to Flu Vaccination in Overweight Men

Almond Immune
Start date: August 12, 2021
Phase: N/A
Study type: Interventional

This research study will test the effects of almonds on immune functions and immune response to influenza vaccine in overweight middle-aged men

NCT ID: NCT05000008 Recruiting - Covid19 Clinical Trials

Aerobic Versus Anaerobic Exercise on Immune Functions and Disease Severity in Patients With COVID-19

Start date: January 1, 2021
Phase: N/A
Study type: Interventional

Participants were assigned randomly into two groups, aerobic exercise and resistance exercise groups. All participants in both groups followed the WHO guidelines of quarantine and used standardized medications given by the physician according to the Turkish Ministry of Health guidelines, including the Hydroxyclorocin Sulphate 200 Mg Film Tablet (Plaquenil 200 Mg Film Tablet). The dose was 2 times/ day, 200Mg/time, for 5 days. Besides, the aerobic exercise group performed moderate-intensity aerobic exercises for 40 min/ 3 sessions/week, 40 minute/session, and the resistance exercise groups 40 min/ 3 sessions/week, 40 minute/session.

NCT ID: NCT04916847 Completed - Immune Response Clinical Trials

Comparative Analysis of Anti-COVID-19 (Severe Acute Respiratory Syndrome) Humoral and Memory T Cell Responses in Children With Various Degrees of Immunosuppression:

PEDIMMCO
Start date: June 7, 2021
Phase:
Study type: Observational

Adaptive immune responses are essential for clearing viral infections and retention of virus specific memory populations is required for long-term immunity. However, there is still uncertainty about whether adaptive immune responses to SARS-CoV-2 are protective. Such knowledge is of immediate relevance, as it will provide insights into immunity of SARS-CoV-2 infection and thus help define future immunization strategies. Because of the importance of asymptomatic cases in children, a specific study is needed in this population in order to determine their individual and collective protective capacity. This is even truer for immune compromised children that likely have severe forms of the disease with active and prolonged viral replication in whom it is therefore essential to determine the extent of sero conversion but also the quality and duration of the memory responses. For this purpose, we plan to analyze the anti-SARS-CoV-2 humoral and memory T cell responses, in different groups of immuno-compromized children (i.e with different levels/type of immunosuppression; HIV, renal or stem cell transplantation, anti-TNF or methotrexate treatment) and healthy controls seen in 3 University Hospitals, in order to determine the proportion of children with SARS-CoV-2 specific humoral responses, their protective capacity, the magnitude and the quality of the SARS-Cov-2 memory T cells but also their long term persistence at 1 year.

NCT ID: NCT04866576 Completed - Inflammation Clinical Trials

Effect of a Fermented Soy Product on Cognition, Immune Status and Vaccine

IS
Start date: August 12, 2021
Phase: N/A
Study type: Interventional

The research study will test the effects of Q CAN PLUS powder on the immune, inflammatory and cognitive functions.

NCT ID: NCT04799808 Recruiting - Clinical trials for SARS-CoV-2 Infection

Saxon SARS-CoV-2 Infection and Vaccination Study in Dialysis Patients, Solid Organ Recipients and Staff

DIA-Vacc
Start date: January 15, 2021
Phase:
Study type: Observational

To investigate short- (3 and 8 weeks) and long-term (6, 9, 12, and 18 months) immune protection or response at the humoral and cellular levels before and after SARS-CoV-2 infection or vaccination in patients with moderately reduced immune status (dialysis patients) and severely reduced immune status (organ transplant recipients, mostly kidney transplant recipients) and immunocompetent subjects (medical staff) in Saxony, Germany.